<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7077318/results/search/disease/results.xml">
  <result pre="7077318 doi: 10.3390/v12020240viruses-12-00240 : Article Structural Basis for Inhibiting Porcine" exact="Epidemic" post="Diarrhea Virus Replication with the 3C-Like Protease Inhibitor GC376"/>
  <result pre="doi: 10.3390/v12020240viruses-12-00240 : Article Structural Basis for Inhibiting Porcine Epidemic" exact="Diarrhea" post="Virus Replication with the 3C-Like Protease Inhibitor GC376 YeGang1†WangXiaowei1†TongXiaohan1ShiYuejun1FuZhen"/>
  <result pre="Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Porcine epidemic" exact="diarrhea" post="virus (PEDV), being highly virulent and contagious in piglets,"/>
  <result pre="structure and catalytic mechanism and plays a key role during" exact="viral" post="polyprotein processing, thus serving as an appealing antiviral drug"/>
  <result pre="with the PEDV 3CLpro and GC376 binding with the transmissible" exact="gastroenteritis" post="virus (TGEV) 3CLpro. Finally, we explored the substrate specificity"/>
  <result pre="PEDV 3CLpro inhibitor crystal structure complex 1. Introduction Porcine epidemic" exact="diarrhea" post="virus (PEDV), which was first observed in Europe in"/>
  <result pre="and causes severe diarrhea, vomiting, dehydration and high mortality in" exact="neonatal" post="piglets, resulting in severe agricultural loss [2,3]. Since PEDV"/>
  <result pre="[4,5,6]. The vaccines based on classic strains failed to control" exact="infection" post="[2]. Furthermore, a vaccine-resistant PEDV strain emerged in the"/>
  <result pre="protease, Nsp5) at 11 conserved sites, which are essential for" exact="viral" post="replication [10,12,13]. Thus, 3CLpro is an appealing target in"/>
  <result pre="antiviral target [23,24,25,26]. Furthermore, two highly pathogenic human coronaviruses, severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome"/>
  <result pre="target [23,24,25,26]. Furthermore, two highly pathogenic human coronaviruses, severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus"/>
  <result pre="[23,24,25,26]. Furthermore, two highly pathogenic human coronaviruses, severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV),"/>
  <result pre="coronaviruses, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), that both came from animals made"/>
  <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), that both came from animals made people"/>
  <result pre="leads to a full recovery in laboratory cats with feline" exact="infectious" post="peritonitis (FIP), a highly fatal feline disease caused by"/>
  <result pre="to a full recovery in laboratory cats with feline infectious" exact="peritonitis" post="(FIP), a highly fatal feline disease caused by feline"/>
  <result pre="cats with feline infectious peritonitis (FIP), a highly fatal feline" exact="disease" post="caused by feline coronavirus (FIPV) that has no commercial"/>
  <result pre="mM and stored at −80 °C. 2.2. Viruses and Cells" exact="African" post="green monkey cells (Vero cells; Cat. No. CCL81, ATCC)"/>
  <result pre="glycerol and 4 mM DTT at pH 8.0 in a" exact="total" post="volume of 100 μL. The enzyme concentration used in"/>
  <result pre="80%–90% confluence, the virus was added at a multiplicity of" exact="infection" post="(MOI) of 0.01 with a series of GC376 concentrations"/>
  <result pre="2 h. Then, the membranes were incubated with an HRP-conjugated" exact="secondary" post="antibody (Boster Biological Technology, Pleasanton, CA, USA) for 40"/>
  <result pre="2% BSA. After blocking, the cells were incubated with the" exact="primary" post="antibody and a FITC-labeled secondary antibody (ThermoFisher, Waltham, MA,"/>
  <result pre="cells were incubated with the primary antibody and a FITC-labeled" exact="secondary" post="antibody (ThermoFisher, Waltham, MA, USA) in the dark. Finally,"/>
  <result pre="which indicates that GC376 quickly enters the cell and blocks" exact="viral" post="3CLpro. Western blot assays were introduced to further quantify"/>
  <result pre="effects of GC376 on the two viruses. Both of the" exact="viral" post="nucleocapsid proteins were decreased in a similar dose-dependent manner"/>
  <result pre="PEDV strains, YN144. Compared with the non-drug-treated cells, GC376 reduced" exact="virus infection" post="at 1.56 μM (Figure 3C). It almost completely inhibited"/>
  <result pre="strains, YN144. Compared with the non-drug-treated cells, GC376 reduced virus" exact="infection" post="at 1.56 μM (Figure 3C). It almost completely inhibited"/>
  <result pre="the buried surface of GC376 took up 76% of the" exact="total" post="solvent-accessible area (computed using the PDBePISA tool, http://pdbe.org/pisa/). As"/>
  <result pre="larger volume. The EC50 of the two compounds fir YN144" exact="infection" post="was measured to evaluate optimization effects. Targets 1 and"/>
  <result pre="effects on PEDV infection. 3.5. Comparison between the PEDV 3CLpro–GC376" exact="Complex" post="and TGEV 3CLpro–GC376 Complex It is reported that GC376"/>
  <result pre="3.5. Comparison between the PEDV 3CLpro–GC376 Complex and TGEV 3CLpro–GC376" exact="Complex" post="It is reported that GC376 shows excellent antiviral activities"/>
  <result pre="reported that GC376 shows excellent antiviral activities against the transmissible" exact="gastroenteritis" post="virus (TGEV), and the structure of TGEV 3CLpro–GC376 complex"/>
  <result pre="the entry and release of the 3CLpro substrate. 4. Discussion" exact="Viral" post="proteases play a vital role in the viral lifecycle"/>
  <result pre="4. Discussion Viral proteases play a vital role in the" exact="viral" post="lifecycle and are confirmed to be ideal antiviral targets."/>
  <result pre="be ideal antiviral targets. Several remarkably potent drugs targeting individual" exact="viral" post="proteases have been developed against important human pathogens, such"/>
  <result pre="have been developed against important human pathogens, such as human" exact="immunodeficiency" post="virus (HIV) and hepatitis C virus (HCV) [45,46,47,48]. This"/>
  <result pre="important human pathogens, such as human immunodeficiency virus (HIV) and" exact="hepatitis" post="C virus (HCV) [45,46,47,48]. This strategy is also applicable"/>
  <result pre="also applicable to coronaviruses, which encode a 3CLpro responsible for" exact="viral" post="polyprotein cleavage. Porcine epidemic diarrhea virus (PEDV), an α"/>
  <result pre="encode a 3CLpro responsible for viral polyprotein cleavage. Porcine epidemic" exact="diarrhea" post="virus (PEDV), an α coronavirus, is one of the"/>
  <result pre="3CLpro, which was slightly higher than that against the transmissible" exact="gastroenteritis" post="virus (TGEV) 3CLpro (0.82 ± 0.47 μM) and lower"/>
  <result pre="transmissible gastroenteritis virus (TGEV) 3CLpro (0.82 ± 0.47 μM) and" exact="lower" post="than that against the SARS-CoV 3CLpro (4.35 ± 0.47"/>
  <result pre="may be affected by the expression level of 3CLpro, other" exact="viral" post="replication characteristics, or the pharmacokinetics of GC376 in different"/>
  <result pre="longer side chain and P2-I/V with shorter side chains showed" exact="lower" post="cleavage efficiency (Figure 5B). This suggests that the length"/>
  <result pre="Two modified compounds, Target 1 and Target 2, both showed" exact="lower" post="inhibitory effects compared to that of GC376. GC376 (L-M)"/>
  <result pre="stretches into the solvent and may not serve as a" exact="primary" post="modification site. Further animal experiments are required to evaluate"/>
  <result pre="are required to evaluate its therapeutic effects on porcine epidemic" exact="diarrhea" post="(PED) in piglets. In general, GC376 exerted an excellent"/>
  <result pre="available vaccinesClin. Exp. Vaccine Res.2015416617610.7774/cevr.2015.4.2.16626273575 3.StevensonG.W.HoangH.SchwartzK.J.BurroughE.R.SunD.MadsonD.CooperV.L.PillatzkiA.GaugerP.SchmittB.J.et al.Emergence of Porcine epidemic" exact="diarrhea" post="virus in the United States: Clinical signs, lesions, and"/>
  <result pre="diarrhea virus in the United States: Clinical signs, lesions, and" exact="viral" post="genomic sequencesJ. Vet. Diagn. Investig.20132564965410.1177/104063871350167523963154 4.LiW.LiH.LiuY.PanY.DengF.SongY.TangX.HeQ.New variants of Porcine"/>
  <result pre="genomic sequencesJ. Vet. Diagn. Investig.20132564965410.1177/104063871350167523963154 4.LiW.LiH.LiuY.PanY.DengF.SongY.TangX.HeQ.New variants of Porcine epidemic" exact="diarrhea" post="virus, China, 2011Emerg. Infect. Dis.2012181350135310.3201/eid1803.12000222840964 5.SunR.Q.CaiR.J.ChenY.Q.LiangP.S.ChenD.K.SongC.X.Outbreak of porcine epidemic"/>
  <result pre="diarrhea virus, China, 2011Emerg. Infect. Dis.2012181350135310.3201/eid1803.12000222840964 5.SunR.Q.CaiR.J.ChenY.Q.LiangP.S.ChenD.K.SongC.X.Outbreak of porcine epidemic" exact="diarrhea" post="in suckling piglets, ChinaEmerg. Infect. Dis.20121816116310.3201/eid1801.11125922261231 6.WangX.M.NiuB.B.YanH.GaoD.S.YangX.ChenL.ChangH.T.ZhaoJ.WangC.Q.Genetic properties of"/>
  <result pre="ChinaEmerg. Infect. Dis.20121816116310.3201/eid1801.11125922261231 6.WangX.M.NiuB.B.YanH.GaoD.S.YangX.ChenL.ChangH.T.ZhaoJ.WangC.Q.Genetic properties of endemic Chinese Porcine epidemic" exact="diarrhea" post="virus strains isolated since 2010Arch. Virol.20131582487249410.1007/s00705-013-1767-723797760 7.HuangY.W.DickermanA.W.PineyroP.LiL.FangL.KiehneR.OpriessnigT.MengX.J.Origin, evolution, and"/>
  <result pre="2010Arch. Virol.20131582487249410.1007/s00705-013-1767-723797760 7.HuangY.W.DickermanA.W.PineyroP.LiL.FangL.KiehneR.OpriessnigT.MengX.J.Origin, evolution, and genotyping of emergent Porcine epidemic" exact="diarrhea" post="virus strains in the United StatesmBio20134e00737-1310.1128/mBio.00737-1324129257 8.ChuH.F.ChenC.C.MosesD.C.ChenY.H.LinC.H.TsaiY.C.ChouC.Y.Porcine epidemic diarrhea"/>
  <result pre="epidemic diarrhea virus strains in the United StatesmBio20134e00737-1310.1128/mBio.00737-1324129257 8.ChuH.F.ChenC.C.MosesD.C.ChenY.H.LinC.H.TsaiY.C.ChouC.Y.Porcine epidemic" exact="diarrhea" post="virus papain-like protease 2 can be noncompetitively inhibited by"/>
  <result pre="mycophenolic acid synergistically inhibit the papain-like protease of Middle East" exact="respiratory" post="syndrome coronavirusAntivir. Res.201511591610.1016/j.antiviral.2014.12.01125542975 16.KumarV.ShinJ.S.ShieJ.J.KuK.B.KimC.GoY.Y.HuangK.F.KimM.LiangP.H.Identification and evaluation of potent Middle"/>
  <result pre="acid synergistically inhibit the papain-like protease of Middle East respiratory" exact="syndrome" post="coronavirusAntivir. Res.201511591610.1016/j.antiviral.2014.12.01125542975 16.KumarV.ShinJ.S.ShieJ.J.KuK.B.KimC.GoY.Y.HuangK.F.KimM.LiangP.H.Identification and evaluation of potent Middle East"/>
  <result pre="syndrome coronavirusAntivir. Res.201511591610.1016/j.antiviral.2014.12.01125542975 16.KumarV.ShinJ.S.ShieJ.J.KuK.B.KimC.GoY.Y.HuangK.F.KimM.LiangP.H.Identification and evaluation of potent Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) 3CL(Pro) inhibitorsAntivir. Res.201714110110610.1016/j.antiviral.2017.02.00728216367 17.KimY.ShivannaV.NarayananS.PriorA.M.WeerasekaraS.HuaD.H.KankanamalageA.C.GroutasW.C.ChangK.O.Broad-spectrum inhibitors against"/>
  <result pre="coronavirusAntivir. Res.201511591610.1016/j.antiviral.2014.12.01125542975 16.KumarV.ShinJ.S.ShieJ.J.KuK.B.KimC.GoY.Y.HuangK.F.KimM.LiangP.H.Identification and evaluation of potent Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) 3CL(Pro) inhibitorsAntivir. Res.201714110110610.1016/j.antiviral.2017.02.00728216367 17.KimY.ShivannaV.NarayananS.PriorA.M.WeerasekaraS.HuaD.H.KankanamalageA.C.GroutasW.C.ChangK.O.Broad-spectrum inhibitors against 3C-like"/>
  <result pre="and feline calicivirusesJ. Virol.2015894942495010.1128/JVI.03688-1425694593 18.KimY.LiuH.KankanamalageA.C.G.WeerasekaraS.HuaD.H.GroutasW.C.ChangK.O.PedersenN.C.Reversal of the progression of fatal" exact="coronavirus infection" post="in cats by a broad-spectrum coronavirus protease inhibitorPLoS Pathog.201612e100553110.1371/journal.ppat.100553127027316"/>
  <result pre="feline calicivirusesJ. Virol.2015894942495010.1128/JVI.03688-1425694593 18.KimY.LiuH.KankanamalageA.C.G.WeerasekaraS.HuaD.H.GroutasW.C.ChangK.O.PedersenN.C.Reversal of the progression of fatal coronavirus" exact="infection" post="in cats by a broad-spectrum coronavirus protease inhibitorPLoS Pathog.201612e100553110.1371/journal.ppat.100553127027316"/>
  <result pre="den ElzenP.AartsE.van den BornE.RottierP.J.M.BoschB.J.Cell attachment domains of the Porcine epidemic" exact="diarrhea" post="virus spike protein are key targets of neutralizing antibodiesJ."/>
  <result pre="complexed with human receptor DPP4Cell Res.20132398699310.1038/cr.2013.9223835475 22.WuK.LiW.PengG.LiF.Crystal structure of NL63" exact="respiratory" post="coronavirus receptor-binding domain complexed with its human receptorProc. Natl."/>
  <result pre="coronavirus main proteasePLoS ONE201510e014486510.1371/journal.pone.014486526658006 25.YangH.YangM.DingY.LiuY.LouZ.ZhouZ.SunL.MoL.YeS.PangH.et al.The crystal structures of severe" exact="acute" post="respiratory syndrome virus main protease and its complex with"/>
  <result pre="main proteasePLoS ONE201510e014486510.1371/journal.pone.014486526658006 25.YangH.YangM.DingY.LiuY.LouZ.ZhouZ.SunL.MoL.YeS.PangH.et al.The crystal structures of severe acute" exact="respiratory" post="syndrome virus main protease and its complex with an"/>
  <result pre="proteasePLoS ONE201510e014486510.1371/journal.pone.014486526658006 25.YangH.YangM.DingY.LiuY.LouZ.ZhouZ.SunL.MoL.YeS.PangH.et al.The crystal structures of severe acute respiratory" exact="syndrome" post="virus main protease and its complex with an inhibitorProc."/>
  <result pre="inhibitors targeting coronavirus main proteasesPLoS Biol.200531742175210.1371/journal.pbio.0030324 27.LiF.Receptor recognition and cross-species" exact="infections" post="of SARS coronavirusAntivir. Res.201310024625410.1016/j.antiviral.2013.08.01423994189 28.WuK.PengG.WilkenM.GeraghtyR.J.LiF.Mechanisms of host receptor adaptation"/>
  <result pre="SARS coronavirusAntivir. Res.201310024625410.1016/j.antiviral.2013.08.01423994189 28.WuK.PengG.WilkenM.GeraghtyR.J.LiF.Mechanisms of host receptor adaptation by severe" exact="acute" post="respiratory syndrome coronavirusJ. Biol. Chem.20122878904891110.1074/jbc.M111.32580322291007 29.YangY.LiuC.DuL.JiangS.ShiZ.BaricR.S.LiF.Two mutations were critical"/>
  <result pre="coronavirusAntivir. Res.201310024625410.1016/j.antiviral.2013.08.01423994189 28.WuK.PengG.WilkenM.GeraghtyR.J.LiF.Mechanisms of host receptor adaptation by severe acute" exact="respiratory" post="syndrome coronavirusJ. Biol. Chem.20122878904891110.1074/jbc.M111.32580322291007 29.YangY.LiuC.DuL.JiangS.ShiZ.BaricR.S.LiF.Two mutations were critical for"/>
  <result pre="Res.201310024625410.1016/j.antiviral.2013.08.01423994189 28.WuK.PengG.WilkenM.GeraghtyR.J.LiF.Mechanisms of host receptor adaptation by severe acute respiratory" exact="syndrome" post="coronavirusJ. Biol. Chem.20122878904891110.1074/jbc.M111.32580322291007 29.YangY.LiuC.DuL.JiangS.ShiZ.BaricR.S.LiF.Two mutations were critical for bat-to-human"/>
  <result pre="29.YangY.LiuC.DuL.JiangS.ShiZ.BaricR.S.LiF.Two mutations were critical for bat-to-human transmission of middle east" exact="respiratory" post="syndrome coronavirusJ. Virol.2015899119912310.1128/JVI.01279-1526063432 30.HulswitR.J.de HaanC.A.BoschB.J.Coronavirus spike protein and tropism"/>
  <result pre="mutations were critical for bat-to-human transmission of middle east respiratory" exact="syndrome" post="coronavirusJ. Virol.2015899119912310.1128/JVI.01279-1526063432 30.HulswitR.J.de HaanC.A.BoschB.J.Coronavirus spike protein and tropism changesAdv."/>
  <result pre="in the subunit association and catalytic action of the severe" exact="acute" post="respiratory syndrome coronavirus main proteaseJ. Biol. Chem.2005280227412274810.1074/jbc.M50255620015831489 34.LeeC.C.KuoC.J.KoT.P.HsuM.F.TsuiY.C.ChangS.C.YangS.ChenS.J.ChenH.C.HsuM.C.et al.Structural"/>
  <result pre="the subunit association and catalytic action of the severe acute" exact="respiratory" post="syndrome coronavirus main proteaseJ. Biol. Chem.2005280227412274810.1074/jbc.M50255620015831489 34.LeeC.C.KuoC.J.KoT.P.HsuM.F.TsuiY.C.ChangS.C.YangS.ChenS.J.ChenH.C.HsuM.C.et al.Structural basis"/>
  <result pre="subunit association and catalytic action of the severe acute respiratory" exact="syndrome" post="coronavirus main proteaseJ. Biol. Chem.2005280227412274810.1074/jbc.M50255620015831489 34.LeeC.C.KuoC.J.KoT.P.HsuM.F.TsuiY.C.ChangS.C.YangS.ChenS.J.ChenH.C.HsuM.C.et al.Structural basis of"/>
  <result pre="of classical and variant virulent parental/attenuated strains of Porcine epidemic" exact="diarrhea" post="virusViruses201575525553810.3390/v710289126512689 39.PensaertM.B.de BouckP.A new coronavirus-like particle associated with diarrhea"/>
  <result pre="epidemic diarrhea virusViruses201575525553810.3390/v710289126512689 39.PensaertM.B.de BouckP.A new coronavirus-like particle associated with" exact="diarrhea" post="in swineArch. Virol.19785824324710.1007/BF0131760683132 40.YeG.DengF.ShenZ.LuoR.ZhaoL.XiaoS.FuZ.F.PengG.Structural basis for the dimerization and"/>
  <result pre="for the dimerization and substrate recognition specificity of Porcine epidemic" exact="diarrhea" post="virus 3C-like proteaseVirology201649422523510.1016/j.virol.2016.04.01827128350 41.OtwinowskiZ.MinorW.Processing of X-ray diffraction data collected"/>
  <result pre="of telaprevir: An NS3-4A protease inhibitor for treating genotype 1" exact="chronic hepatitis" post="C virusNat. Biotechnol.201129993100310.1038/nbt.202022068541 47.HoweA.Y.VenkatramanS.The discovery and development of boceprevir:"/>
  <result pre="telaprevir: An NS3-4A protease inhibitor for treating genotype 1 chronic" exact="hepatitis" post="C virusNat. Biotechnol.201129993100310.1038/nbt.202022068541 47.HoweA.Y.VenkatramanS.The discovery and development of boceprevir:"/>
  <result pre="and development of boceprevir: A novel, first-generation inhibitor of the" exact="hepatitis" post="C virus NS3/4A serine proteaseJ. Clin. Transl. Hepatol.20131223210.14218/jcth.2013.002xx26357603 48.LvZ.ChuY.WangY.HIV"/>
  <result pre="and the inhibitory effect of GC376 on the porcine epidemic" exact="diarrhea" post="virus (PEDV) 3CLpro determined by FRET assays. (A) GC376"/>
  <result pre="cell culture. (A) CV777 was added at a multiplicity of" exact="infection" post="(MOI) of 0.01 with a series of GC376 concentrations"/>
  <result pre="at a series of concentrations. The cells were treated with" exact="primary" post="antibody (anti PEDV N) and then a FITC-labeled secondary"/>
  <result pre="with primary antibody (anti PEDV N) and then a FITC-labeled" exact="secondary" post="antibody. The cells infected by viruses were captured in"/>
  <result pre="Figure 6 Structure alignment between the PEDV 3CLpro–GC376 and transmissible" exact="gastroenteritis" post="virus (TGEV) 3CLpro–GC376. (A) The structure of PEDV 3CLpro–GC376"/>
  <result pre="1Table 1 Data collection and refinement statistics. PEDV 3CLpro in" exact="Complex" post="with GC376 Data Collection Space group P 1 21"/>
  <result pre="refinement statistics. PEDV 3CLpro in Complex with GC376 Data Collection" exact="Space" post="group P 1 21 1 Cell parameter (a, b,"/>
  <result pre="0.011 Bond angle (Å) 1.10 Average B factor (Å2) 29.34" exact="Protein" post="28.75 Water 35.08 Ligand 41.97 Ramachandran plot: core, allow,"/>
 </snippets>
</snippetsTree>
